Cistanche tubulosa: Difference between revisions
Jump to navigation
Jump to search
(Created page with "This is Novel in UK and EU and not approved. The European Food Safety Authority (EFSA) concluded that the safety of a water extract of Cistanche tubulosa stems as a novel food ingredient has not been established. EFSA's Panel on Nutrition, Novel Foods and Food Allergens (NDA) raised safety concerns due to adverse events reported in clinical trials, including severe events like cerebral haemorrhage and epilepsy. Consequently, the European Commission terminated the proced...") |
No edit summary |
||
| Line 2: | Line 2: | ||
The European Food Safety Authority (EFSA) concluded that the safety of a water extract of Cistanche tubulosa stems as a novel food ingredient has not been established. EFSA's Panel on Nutrition, Novel Foods and Food Allergens (NDA) raised safety concerns due to adverse events reported in clinical trials, including severe events like cerebral haemorrhage and epilepsy. Consequently, the European Commission terminated the procedure for authorizing the extract as a novel food. This was in 2021, no further applications have been made. | The European Food Safety Authority (EFSA) concluded that the safety of a water extract of Cistanche tubulosa stems as a novel food ingredient has not been established. EFSA's Panel on Nutrition, Novel Foods and Food Allergens (NDA) raised safety concerns due to adverse events reported in clinical trials, including severe events like cerebral haemorrhage and epilepsy. Consequently, the European Commission terminated the procedure for authorizing the extract as a novel food. This was in 2021, no further applications have been made. | ||
[[Category:Novel Food]] | |||
[[Category:Ingredients]] | |||
Latest revision as of 09:35, 14 November 2025
This is Novel in UK and EU and not approved.
The European Food Safety Authority (EFSA) concluded that the safety of a water extract of Cistanche tubulosa stems as a novel food ingredient has not been established. EFSA's Panel on Nutrition, Novel Foods and Food Allergens (NDA) raised safety concerns due to adverse events reported in clinical trials, including severe events like cerebral haemorrhage and epilepsy. Consequently, the European Commission terminated the procedure for authorizing the extract as a novel food. This was in 2021, no further applications have been made.